Taiwan Tfda Medical Device Registration Service

Scope and evidence must be confirmed before any paid tests or filings.

A Taiwan TFDA medical device registration filing is not just a document upload. The safe sequence is to confirm the regulatory route, establish the Taiwan-side applicant, align the manufacturer and product evidence, submit the correct administrative and technical package, answer TFDA deficiencies on time, and then maintain the approval after issuance. For imported devices, the applicant and the foreign manufacturer must also keep the authorization, free-sale evidence and quality-system status consistent with the filed product.

Start by fixing the filing route

Taiwan regulates medical devices under the Medical Devices Act. Devices are classified by risk, but not every Class I product follows the same market-entry mechanism. The Act allows TFDA to designate certain products for listing, while devices outside that listing route require registration and market approval before manufacture or import. Class II and Class III applications follow the registration-and-license route.

Question to resolve first	Why it changes the filing	Safe action before dossier build
Is the product a medical device under Taiwan rules?	The product definition and intended use determine whether TFDA medical-device rules apply at all.	Freeze intended use, mechanism of action and product description before selecting the category.
What is the Taiwan classification and item number?	Class and item drive the evidence set, review depth and whether a predicate-based route is available.	Match the device against TFDA classification rules and approved predicates, not only an EU or US class.
Is the product eligible for listing instead of a license?	Some products announced by TFDA use the listing system; other devices must use registration and market approval.	Do not assume every Class I device needs the same application package.
Is the product an IVD?	IVDs have product-specific filing considerations and should not be treated as a generic non-IVD dossier.	Use the dedicated Taiwan TFDA IVD registration service scope for an IVD filing.

If the real need is route selection, classification strategy or a gap assessment before execution, that belongs to the Taiwan TFDA medical device registration consultant scope. This page focuses on filing execution.

Who files: the Taiwan applicant must be established before submission

For a registration application, TFDA requires a copy of the medical device business permit. An importer must hold the relevant medical-device dealer permit showing the import business category. For an imported device, the foreign original manufacturer must authorize a Taiwan agent to apply for registration and market approval and cooperate with that agent on regulatory compliance.

The authorization letter should identify the Taiwan medical device firm and the device name plus specifications and/or model numbers. TFDA states that this authorization is valid for one year from issuance. If it is not in English, a Chinese or English translation must be submitted. The authorization details should be checked against the free-sale/manufacture evidence before filing, because mismatched manufacturer names, addresses, device names or model scopes are a common avoidable source of questions.

Build the dossier in two controlled layers

For Class II and Class III devices, the filing is easiest to control when the administrative layer and technical layer are built separately and reconciled before submission.

Dossier layer	Core content	Execution check
Administrative	Application form; two copies of draft labels, instructions or packaging; medical device business permit; manufacture and free-sale certificate for imported products where required; foreign manufacturer authorization; evidence of QMS conformity where required.	Names, addresses, legal manufacturer, applicant, product name, model range and intended use must be mutually consistent.
Technical	Preclinical test specifications and methods, original test records and reports; structure, materials, specifications, functions, intended use and drawings; clinical evidence when required; radiation-safety information for ionizing-radiation equipment; EP/STED documentation where applicable; other TFDA-designated evidence.	Every claim in the labeling and intended use should be traceable to the technical evidence actually filed.

TFDA's Class II/III appendix allows different evidence treatments in defined situations. For example, certain Class II products with a Taiwan-approved predicate may use specified alternative evidence, and clinical evidence may be exempted where a predicate exists unless TFDA considers clinical verification necessary. These are conditional routes, not blanket waivers. A service provider should document why the chosen alternative applies to the exact device rather than simply deleting test or clinical material from the dossier.

Imported-device documents need their own validity control

The manufacture and free-sale certificate for an imported device must identify the product and manufacturer and confirm manufacturing and lawful sale in the country of origin. TFDA's guidance states that this certificate is generally valid for two years from issuance and requires Taiwan overseas-office authentication unless an applicable exemption applies. If the document is not issued in English, a Chinese or English translation is required and, where applicable, authenticated as well.

Because the authorization letter and the free-sale/manufacture certificate have different validity periods and formalities, they should be tracked separately. Do not obtain them too early without checking the planned filing date.

Quality-system readiness can block an otherwise complete product file

Medical-device manufacturers are subject to Taiwan's Medical Device Quality Management System requirements unless the specific product/manufacturer situation falls within an announced exemption or reduced requirement. For foreign manufacturers of imported devices, TFDA provides a QSD conformity-assessment process through its online QMS application platform. TFDA currently states a fee of NT$60,000 for the standard foreign-manufacturer QSD conformity assessment and NT$30,000 for the essential application mode limited to eligible Article 78 items.

QMS status should therefore be treated as a parallel workstream, not as an attachment to chase after the product dossier is finished. The product registration package should use the same manufacturer identity and site data as the QMS/QSD records.

Submission workflow: what happens after the dossier is ready

Lock the product scope. Confirm classification, item number, intended use, legal manufacturer, models and whether accessories require separate filings.
Confirm the Taiwan applicant. Verify the business permit and import scope where applicable, then execute the foreign-manufacturer authorization for imported products.
Close the administrative evidence. Check document validity, authentication/translation requirements, product naming and consistency across certificates.
Close the technical evidence. Reconcile labeling claims against testing, product description, predicate comparison, clinical evidence and any special safety material.
Submit by the current permitted channel. TFDA's current instructions for Class II/III filings provide for electronic submission, mail or counter submission, while certain application categories have been made mandatory electronic filings since 1 July 2025 unless TFDA accepts a paper exception.
Pass formality review. If TFDA finds correctable administrative incompleteness, the regulations provide a one-month correction period. Missing the deadline can lead to rejection.
Pass substantive review. If technical or substantive information is incomplete but correctable, TFDA may request correction within three months. Missing that deadline can also lead to rejection.
Complete issuance. After an approval notice, the applicant must pay the license fee and prepare labels, instructions or packaging in the approved form within three months to obtain the license.

Application splitting and scope control

TFDA states that products with the same classification number, identical product name, manufacturer and intended use, but different model numbers, may be combined under one registration application. Different product names under the same class and classification are filed separately. TFDA also states that Class II or III accessories that are not exclusive to the proposed device must be filed under a separate registration-and-market-approval application.

This makes the model matrix a filing-control document. Before submission, list every model, accessory, intended-use difference, sterile status and technical difference and decide whether each item stays in the same application or must be separated. A poorly controlled model scope can create inconsistent labels, certificates and test coverage.

Common rejection or delay triggers

Applicant problem: the Taiwan firm does not hold the required medical-device business/import permit for the intended activity.
Authorization mismatch: the foreign manufacturer's letter does not match the applicant, manufacturer, product name or model scope shown elsewhere.
Expired or incorrectly authenticated evidence: the free-sale/manufacture certificate or authorization letter is outside its stated validity or lacks required translation/authentication.
Over-broad application: different product names, non-exclusive accessories or materially different configurations are forced into one file without a defensible basis.
Technical-evidence gap: performance, safety, biocompatibility, electrical/EMC, clinical or other evidence does not support the exact claims and configuration being registered.
QMS identity mismatch: manufacturer/site information in the product application does not line up with the QMS/QSD status.
Missed TFDA response deadline: a formality or substantive deficiency response is not filed within the applicable correction period.

After approval: the file becomes a lifecycle obligation

A Taiwan medical device license is valid for no more than five years. If continued manufacture or import is needed, an extension must be filed before expiry; the licensing regulations require an extension application within the six months before the expiry date. Certain changes to approved particulars, including product name, labeling, materials/structure/specifications/models, intended use, manufacturer data or license holder, require a change application before implementation unless a specific self-change rule applies.

Do not confuse license maintenance with the separate annual-declaration rule for products that use TFDA's listing system. Listed products that have been listed for a full year must make the annual declaration in the Listing System in October. A registration service should therefore end with a maintenance calendar that identifies license expiry, QMS/QSD expiry, authorization-document renewal needs and change-control triggers.

Execution responsibility matrix

Workstream	Foreign manufacturer	Taiwan applicant / license holder	Registration execution team
Product definition	Provide intended use, models, design and manufacturer data.	Confirm Taiwan filing scope and local business status.	Build the filing matrix and identify split/combined applications.
Administrative documents	Issue authorization and obtain country-of-origin evidence.	Provide business permit and sign/submit local forms.	Run consistency, validity, translation and authentication checks.
Technical dossier	Provide test reports, product description, risk/clinical and labeling source material.	Coordinate local-language and TFDA-facing documentation.	Map evidence to TFDA requirements and prepare deficiency responses.
QMS/QSD	Provide manufacturing-site and quality-system evidence.	Coordinate Taiwan-side application data.	Keep QMS and product-registration identities aligned.
Post-approval	Notify design, site, labeling or intended-use changes early.	Maintain the license/listing and local regulatory communications.	Assess change filing, renewal and document-refresh requirements.

What should be prepared before instructing a filing service

At minimum, prepare the product's intended use, current labels/IFU, full model and accessory list, legal-manufacturer and manufacturing-site details, existing market approvals/free-sale evidence, current QMS certificates and audit status, available preclinical/performance/biocompatibility/electrical/EMC/sterilization/software/clinical evidence as relevant, and a list of any differences between the product sold in other markets and the version intended for Taiwan. With that package, the filing team can identify missing evidence before formal submission instead of discovering it after TFDA starts the review clock.

Official sources

FAQ

Can a foreign manufacturer file directly with TFDA?

For an imported-device registration, the filing package includes a Taiwan medical device firm's business permit and a foreign-original-manufacturer authorization naming the Taiwan agent authorized to apply. In practice, the Taiwan-side applicant must therefore be established before the imported-device filing is submitted.

Does every Class I device use the same registration route?

No. Taiwan law allows TFDA to designate certain devices for listing, while devices that are not in that listing route require registration and market approval. The exact product item must be checked before building the dossier.

Can several models be covered by one TFDA application?

Potentially. TFDA states that models may be combined where the classification number, product name, manufacturer and intended use are identical and the difference is only the model number. Other differences can require separate treatment, so the model matrix should be reviewed before filing.

Does an EU CE mark or US clearance replace the Taiwan technical dossier?

No blanket replacement rule should be assumed. TFDA provides defined alternative-evidence routes for some products, including certain Class II predicate situations, but the conditions must be checked against the exact device. Foreign approval can support a route; it does not by itself erase Taiwan filing requirements.

What happens if TFDA finds the application incomplete?

The regulations distinguish formality and substantive review. Correctable formality deficiencies are subject to a one-month correction period, while correctable substantive deficiencies are subject to a three-month period. Failure to respond by the designated deadline can result in rejection.